Introduction
Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia in the western hemisphere, is a clonal hematopoietic disorder characterized by the accumulation of matureappearing, immunologically incompetent, usually B cell lineage lymphocytes, with a long life-span. [1] [2] [3] The disease occurs mainly at an older age, but up to 40% of patients with B-CLL are younger than 60 years of age at diagnosis and 10% are less than 50 years of age. 4, 5 Whereas many patients at older ages will ultimately die of unrelated causes due to their age, most younger patients will die of progressive B-CLL and its complications. The younger subgroup of patients have a significantly shorter survival rate than their normal age-matched counterparts, since conventional treatment is not able to cure CLL. 5 This patient group might therefore benefit from more aggressive treatment, for example, allogeneic stem cell transplantation (SCT). Around 100 patients with CLL have been reported after SCT. 6 Several reports have shown that SCT may eradicate the disease and induce long-lasting remission. [6] [7] [8] Clonal rearrangement of the immunoglobulin heavy-chain locus (IgH) by use of the polymerase chain reaction (PCR) provides a useful marker for detecting minimal residual disease (MRD) in B-CLL. [8] [9] [10] Some authors have reported a correlation between persistence of PCR-detectable MRD and subsequent relapse in patients with CLL after SCT. 8 PCR amplification of variable number tandem repeat regions (VNTRs) has been used to evaluate various degrees of donor and recipient mixed chimerism (MC), post-SCT. 11, 12 Whether MC is related to relapse post-SCT has been a matter of debate. 13 We studied both MC and MRD after SCT in patients with B-CLL. MC within the B cell fraction was compared to MRD in peripheral blood (PB) and bone marrow (BM). A quantitative cytokine assay for tumor necrosis factor-␣ (TNF-␣) and soluble interleukin-2 receptor (sIL-2R) was also performed, to monitor the tumor burden pre-and post-SCT.
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Materials and methods
Patients
Six patients with a diagnosis of B-CLL, as defined by the National Cancer Institute, were included. 16 The patient characteristics before SCT are summarized in Table 1 . The median time from diagnosis to SCT was 4.5 years (0.7-5 years). Before SCT, all patients had a response to last therapy. However, UPN 474 showed signs of progressive disease just prior to SCT. This was also the only patient showing a verified Richter's transformation pre-SCT. At SCT, three patients were classified as Binet stage C, because of treatment-related anemia or thrombocytopenia, and three patients as Binet stage A. All patients, except one, had morphological and phenotypical signs of remaining disease.
SCT was performed between January 1994 and December 1997 at the Centre for Allogeneic Stemcell Transplantation, Huddinge Hospital. All donors were HLA-identical siblings. The preparative regimen consisted of cyclophosphamide (CTX) 60 mg/kg on 2 consecutive days followed by 10 Gy of total body irradiation (Table 2) , as previously described. 17 In addition, one patient (UPN 581) received fludarabine 35 mg/m 2 on 2 consecutive days before CTX. As prophylaxis against GVHD, cyclosporine A (CsA) was combined with a short course of methotrexate (MTX) in all patients. 18 Details regarding the transplantation procedure and supportive care have been published elsewhere.
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Definition of response
Complete response (CR) and partial response (PR) was defined according to Working Group Guidelines for CLL. 16 In summary, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of constitutional symptoms, normal blood counts and normal BM aspirate and biopsy for a period of at least 2 months after therapy was required for CR. Partial response required Ͼ50% decrease in peripheral lymphocyte count from pre-treatment value, Ͼ50% reduction in lymphadenopathy, and/or Ͼ50% reduction in hepatomegaly/ splenomegaly for a period of at least 2 months after therapy and one out of three additional defined criteria.
PCR amplification template preparations
DNA from donor and recipient pretransplantation samples was extracted, using standard protocols (Qiagen, Hilden, Germany). To evaluate lineage-specific chimerism, separation of CD3-, CD19-, CD45-positive cells from 4 ml of EDTA PB or BM was done using immunomagnetic beads, according to the manufacturer's instructions (Dynal, Oslo, Norway). To each cell pellet, 30 l 10 mm Tris buffer was added before freezing. After thawing, 60 l lysis buffer (18 l 5× red cell lysis buffer (1.6 m sucrose, 0.05 m Tris-HCl, 25 mm MgCl 2 -6H 2 O, 5% Triton-X-100, 0.01 m Tris-Base), 8 l proteinase K (10 mg/ml), 34 l dH 2 O) was added to each bead-separated sample. Samples were then digested at 37°C overnight on a shaker. CD19-positive samples were diluted in 100-300 l 10 mm Tris buffer, pH 6.6. CD3-positive and CD45-positive samples were diluted in 1000 l 10 mm Tris buffer, pH 6.6. Prior to PCR, diluted cell lysate samples were heated to 70°C for 10 min and then spun for 1 min at 6150 g in a microcentrifuge, and cooled on ice. For chimerism analysis, PCR amplification was performed using 10 ng of genomic DNA or 2 l (10-20 ng) of cell lysate DNA. Genomic DNA concentrations were measured in a Gene Quant II spectrophotometer (Pharmacia, Uppsala, Sweden), whereas cell lysate DNA was estimated by a semiquantitative dotMETRIC assay (NMI, San Diego, CA, USA).
VNTR analysis
PCR amplification of six different minisatellite loci was used for analysis of MC. [20] [21] [22] [23] [24] [25] All oligonucleotide primers were synthesized commercially (Cybergene, Huddinge, Sweden). Each final PCR reaction (10 l) contained 0.5 m of each primer, 200 m of each dNTP (Perkin Elmer, Branchburg, CA, USA), 1× PCR buffer (50 mm Mg, 10 mm KCl, 0.001% gelatin), 5% glycerol, 1 ng cresol red, 10-20 ng genomic DNA, 0.3 U AmpliTaq polymerase (Perkin Elmer). After an initial 3 min hot-start/denaturation step at 94°C, 32 PCR amplification cycles were carried out in a PTC-200 thermal cycler (MJ Research, Watertown, CA, USA). The first 10 amplification cycles were done in a two-segment step at 94°C for 15 s and at 65°C for 1 min. The following 22 cycles were done in a three-segment step at 94°C for 15 s, 61°C for 50 s and 72°C for 30 s. PCR amplified products were run on a ready-to-use PAGE system (Pharmacia Biotech). 12.5% non-denaturing polyacrylamide gels were run for 1.5 h under standard buffer conditions at 10°C in a Genephor peltier-cooled gel apparatus (Pharmacia Biotech). PCR amplified band patterns were analyzed in visible light after a 90-min automated silver staining procedure (Pharmacia Biotech). We used a semiquantitative estimation of MC, where recipient-band intensity was compared to donor-band intensity on a four-degree scale. MC +3 indicated equal recipient-donor band intensity, whereas MC Sensitivity of mixed chimerism (MC) analysis. Recipient B cells were immunomagnetically separated and the antibodies were detached. B cells were counted and diluted in donor whole blood with a known total white cell concentration. The CD19-positive cells were immunomagnetically immobilized, lysed and PCR was performed directly on cell lysate DNA.
+1, +2 indicated less and MC +4 indicated more recipientband intensity. After digital photodocumentation, PAGE gels were sealed in hybridization bags and stored at +4°C, for future reference.
Analysis of IgH gene rearrangement
PCR amplification of IgH genes used a degenerate primer complementary to framework three (FR3) of the variable (V H ) gene segments, together with a consensus joining (J H ) 1-6 gene segment primer (Table 3) . 26, 27 PCR amplification conditions were identical with VNTR amplification conditions, except that 200 ng DNA was used in each PCR amplification reaction and that 35 amplification cycles were carried out. DNA was extracted from leukemia cells obtained at diagnosis. PCR products were electrophoresed, and single bands were excised from preparative 2% GTG agarose gels. Excised bands were purified using the QIAquick Gel Extraction Kit (Qiagen), according to the guidelines of the manufacturer. Purified PCR products were ligated into TA vectors and subsequently transformed into competent cells, as described in the pGEM-T Easy Vector System 1 protocol (Promega, Madison, WI, USA). Plasmids from 10 independent clones were purified, using the Plasmid Mini Kit (Qiagen), and unidirectionally sequenced with a T7 vector-specific primer, using the ABI prism Big Dye 
V, D and J refer to variable, diversity and joining gene segments of the IgH gene. Primers used for PCR amplification of the IgH gene segments were FR3: 5Ј-ACACGGC(C/T)(G/C)TGTATTACTGT-3Ј and Jpst: 5Ј-AACTGCAGAGGAGACGGTGACC-3Ј. Nucleotide sequences used as patient-specific primers are underlined. The sequence of the N2 region was used for specificity control of patient-specific primers.
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Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer). Sequences were analyzed on a 373A DNA sequencer (Applied Biosystems, Foster City, CA, USA). The predominant nucleotide sequence derived from the various plasmid clones of each patient was studied. The sequence from the N1 regions (Table 3 ) of rearranged IgH genes was used to accommodate the 3Ј-end of the 5Ј-patient-specific primer used for each patient. After an initial 3-min hot-start/denaturation step, 35 PCR amplification cycles were carried out in a PTC-200 thermal cycler (MJ Research). The first 10 amplification cycles in a two-segment step were done at 94°C for 20 s and at 65°C for 1 min. The following 25 cycles in a three-segment step were done at 94°C for 20 s, 61°C for 50 s and 72°C for 20 s. PCR amplified specific products of 80-120 bp size were analyzed on the same PAGE system, as described for VNTR analysis. To prove that a PCR product from a post-SCT sample was identical to the original leukemic clone, sequencing (as described above) was performed on most of the positive post-SCT samples. The retrieval of a correct N2 sequence was considered evidence of clonal identity.
Cytokine assay
Samples from PB were immediately centrifuged and the sera were frozen at −86°C, pending analysis. TNF-␣ and sIL-2R were analyzed using the Quantikine ELISA kit from R&D (Minneapolis, MN, USA). Assays were performed according to the manufacturer's instructions. In brief, samples and standards were incubated in cytokine-antibody precoated wells. After washing, a polyclonal antibody conjugated to horseradish peroxidase was added. After incubation and washing, a cromogen-peroxide substrate solution was added. The color development was stopped with sulfuric acid and the intensity of the color was measured. Intra-assay c.v. were 5.6% and 4.7% for soluble IL2R and TNF-␣, respectively; intra-assay c.v.: 6.7% and 5.8%, respectively. Sensitivities were 24 pg/l and 4:4 pg/l, respectively. Mean levels of sIL-2R in 37 serum samples from healthy normal controls were 1346 pg/ml (range 676-2132 pg/ml). Levels of TNF-␣ were not detected in any of 40 serum samples from healthy normal controls.
Figure 2
Results of chimerism analysis and minimal residual disease (MRD) over time in six patients with B-CLL after allogeneic SCT. The first three samples from UPN 554 and all samples from UPN 428 and 474 were analyzed with DNA extracted from peripheral blood slides. In all other samples, cell-lysate DNA from CD19-positive cells was used for chimerism detection. DC, donor chimerism; MC, mixed chimerism; RD, remaining disease; CR, complete remission.
Results
Patients
All patients showed a response to SCT. Five patients are alive, four of them in complete remission (CR), with a median follow-up time of 24 months (15-60). One patient died due to pneumonia 23 months after SCT, without clinical progression. UPN 474 and 621 had remaining lymphocytosis, which normalized 7 and 10 months after SCT, respectively. Three patients were classified as being in CR by morphology and also by immunophenotype analysis on all BM aspirations taken post-SCT, whereas UPN 428 and 474 had signs of persistent disease 6 months post-SCT, but showed CR at 12 months and thereafter. In UPN 621, persistent disease was found on all BM examinations after SCT. All patients developed acute and chronic GVHD ( Table 2) . UPN 428 developed a hemolytic uremic syndrome 1 year post-SCT, which responded well to treatment. UPN 621 has developed an aseptic necrosis of the hip.
Sensitivity of PCR amplification
When tested on DNA dilution series, all six VNTRs had a sensitivity at the 2% level. In a cell dilution series, B cells of individual 'A' were diluted in whole EDTA blood with a known total WBC of individual 'B'. CD19-positive cells were then immunomagnetically collected in an 'affected celllineage'-specific manner and a sensitivity down to 2 × 10
was obtained, probably due to reduction of the irrelevant background ( Figure 1 ). Using IgH patient-specific primers and a DNA template concentration of 200 ng in each PCR reaction, a sensitivity of 1 × 10 −4 was routinely achieved (data not shown).
Chimerism analysis
UPN 428 and 474 were retrospectively analyzed using BM and PB slides. Therefore, immunomagnetic cell separation could not be performed. MC was detected in all patients, except UPN 554, who was donor chimeric in all samples analyzed. In UPN 581, 609 and 621 who had MC in the CD19 − cell fraction, MC corresponded to detection of MRD in 25 out of 26 samples (Figure 2) . In UPN 621, the chimerism pattern changed during the first year and the patient became a complete donor chimera in the CD3 + (T cells) and CD45 + cell fractions (mainly granulocytes). However, the CD19 + cells continued to be of recipient origin (Figure 3) . UPN 581 and 609 also showed MC in the CD3 + and CD19 + cells up to 9 and 3 months post-SCT, respectively (Figure 4 ). In these latter two patients, a comparison between immunomagnetic cell separation and extraction of DNA from whole blood was performed in seven and six corresponding samples, respectively. In both patients, MC was detected in the cell separated samples, but not in the DNA-extracted samples (Figure 4) . A comparison of MC and MRD in PB and BM was also made in all patients on 15 simultaneous occasions post-SCT. The results were concordant for both PB and BM, with five of 15 positive MC and MRD samples. Comparison of chimerism and MRD analysis in UPN 621 on three different occasions post-SCT. Chimerism analysis was performed on immunomagnetically separated cells while MRD was analyzed with DNA extracted from whole blood and cell lysate DNA from CD19 separated cells.
Figure 4
Chimerism analysis in UPN 581. The figure compares chimerism analysis performed on cell-lysate DNA from immunomagnetically separated cells with DNA extracted from whole blood.
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MRD detection
A monoclonal IgH-sequence was retrieved from the diagnostic samples of all patients, and patient-specific primers could be readily designed. All six patients were MRD positive before SCT. The median time from diagnosis to the last positive MRD sample, with retrieval of the correct sequence, was 3 years (1-7 years). Despite morphological and immunophenotype remission, UPN 428 and 474 proved to be MRD-positive up to 37 and 23 months post-SCT, respectively. In UPN 581 and 609, with MC in the CD19 + cell fraction, the retrieval of the leukemic clone-specific sequence was detected in the same samples (Figure 2) . UPN 621 was found to be highly MRD positive in all analyzed samples (Figures 2 and 3) , whereas in UPN 554, MRD was only detected on day +21 post-SCT.
Cytokine levels
Before starting the conditioning, the levels of sIL-2R and TNF-␣ were higher in all patients than in normal controls. The levels were particularly high in the three patients with most advanced disease prior to SCT (Table 1, Figure 5 ). After SCT, the levels of sIL-2R in the latter three patients slowly fell. Short high-peak levels were seen during acute GVHD in these three patients. Patient 474 also showed an increase in sIL-2R during chronic GVHD at 200 days post-SCT ( Figure 5 ). One year after SCT, levels of sIL-2R were normal in all patients, except UPN 474 and 621 ( Figure 5 ). In patients with less advanced disease, levels of sIL-2R returned to normal within 3 to 6 months (data not shown). During the first 6 months after SCT, TNF-␣ showed spikes in the levels of patients with Binet stage C (UPN 428, UPN 474 and UPN 621) pre-SCT and in UPN 581. In the remaining two patients with Binet stage A, the levels were undetectable. One year post-SCT, TNF-␣ levels could be detected only in the two patients with most advanced disease, ie UPN 474 and UPN 621.
Discussion
Although only a few patients with CLL have received SCT over the last decade, its feasibility has been substantiated. 7, 28, 29 One aim of the present study was to determine whether SCT could eradicate PCR-detectable MRD in patients with CLL, and if there was any correlation between the degree of tumor burden pre-SCT and MRD positivity post-SCT. Hardly any studies have addressed these questions before, but it has been proposed that MRD detection post-SCT is related to an increased risk of relapse in patients with B-CLL. 8 In the study by Provan et al 8 two patients out of 10 were MRD positive after SCT, and both had a relapse 2 years after SCT. This is in contrast to our results, where all patients were MRD positive early post-BMT. UPN 428, in whom MRD was detected more than 3 years post-SCT, without evident relapse, illustrates that detectable MRD does not necessarily cause hematological relapse. The three patients with the most advanced disease prior to SCT, as assessed by the stage of the disease and cytokine analysis, also had the most persistent MRD after SCT. Detectable MRD post-SCT may therefore reflect the tumor burden pre-SCT, in combination with a slow proliferative rate of the malignant cells per se and resistance to high-dose chemotherapy. Consequently, CLL patients may need more time to eradicate residual disease. 30, 31 MRD and MC disappeared shortly after SCT in patient 554, which may be due to the myeloablative therapy. In patient 609 MRD and MC disappeared after 4 months and in patient 428 after more than 3 years. This may be due to a GVL effect by acute and chronic GVHD in these two patients. The GVL effect is most prominent after chronic GVHD. 32 All our patients experienced acute as well as chronic GVHD. Cyclosporine may have an antiproliferative effect on B-CLL. 33 However, all patients in this study received cyclosporine in equivalent doses and for a prolonged, but limited, period of time post-SCT. Still, the patients showed different molecular MRD patterns post-SCT. There are earlier reports of a GVL effect in patients with CLL, in whom it has also been suggested that the GVL effect may contribute to control of the disease after transplant. 30, 34, 35 These results may also indicate a potential role for additional immunotherapy by donor T cell infusions post-SCT, especially in patients with persistent MRD.
Chimerism analysis after SCT has been reported in only a few patients with CLL. Martino et al 36 studied three in whom they observed various patterns of chimerism with no evidence of residual disease (using DNA extraction from whole blood). In the present study, we showed with immunomagnetic cell separation that we increased not only the informative value of chimerism analysis, as shown in UPN 621, but also the sensitivity of the technique.
An important question is whether BM should be used or if PB is just as good for detecting MRD. Gribben et al 37 demonstrated that BM was a better source than PB in patients with non-Hodgkin's lymphoma, using PCR amplification of the t (14;18) . In CML patients, Lin et al 38 analyzed for evidence of BCR-ABL mRNA by using RT-PCR in BM and PB, and showed that the results from the two sources were similar in all cases. Although few samples from BM and PB were compared in this study, all with concordant results, we suggest that PB can be used in this patient group as well as BM.
It has been suggested that sIL-2R and TNF-␣ might represent a reliable marker of tumor burden in CLL. 14, 15, 39 In keeping with this, the highest levels were detected in the patients with most advanced disease, especially in UPN 474 who had signs of progressive disease at SCT. After transplant, the levels fell in all patients and showed a definite relationship to the response of the disease, except in UPN 474 who, at 200 days post-SCT, had peak values which were probably due to an exacerbation of chronic GVHD. Moreover, only patients with persistent molecular disease showed peaks in the levels of TNFa during the first 6 months post-SCT. TNF-␣ has been proposed as an autocrine growth factor for B-CLL cells and has also been shown to enhance the expression of the survival protein BCL-2, which is known to inhibit apoptosis. [40] [41] [42] [43] [44] [45] UPN 474 and 621, who showed the highest level of residual disease, were the only patients with detectable TNF-␣ more than 1 year post-SCT.
In summary, MRD is common in patients with CLL after SCT and prolonged persistence of residual disease may be correlated to the severity of tumor burden pre-SCT. Therefore, we conclude that successful allogeneic stem cell transplantation in patients with CLL requires a durable anti-leukemic effect. Further immunotherapy may play a role in controlling this disease.
